Stephens Begins Coverage on OptimizeRx (NASDAQ:OPRX)

Analysts at Stephens began coverage on shares of OptimizeRx (NASDAQ:OPRX) in a research report issued on Friday, Marketbeat Ratings reports. The firm set an “equal weight” rating and a $5.50 price target on the stock. Stephens’ target price would suggest a potential upside of 12.02% from the stock’s previous close.

OPRX has been the topic of a number of other research reports. Stifel Nicolaus lowered their target price on shares of OptimizeRx from $13.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, November 14th. William Blair reissued an “outperform” rating on shares of OptimizeRx in a report on Thursday, November 14th. Barclays cut their target price on OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating for the company in a research report on Thursday, November 14th. Roth Mkm reiterated a “buy” rating and issued a $16.00 price target (down from $20.00) on shares of OptimizeRx in a research report on Thursday, November 14th. Finally, Royal Bank of Canada cut their price objective on OptimizeRx from $14.00 to $7.00 and set an “outperform” rating for the company in a report on Thursday, November 14th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $9.71.

OptimizeRx Stock Up 3.4 %

OPRX opened at $4.91 on Friday. OptimizeRx has a fifty-two week low of $3.78 and a fifty-two week high of $16.65. The company has a market capitalization of $90.45 million, a P/E ratio of -3.69 and a beta of 1.34. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.23 and a quick ratio of 3.23. The firm’s fifty day moving average price is $5.37 and its two-hundred day moving average price is $7.82.

Insider Transactions at OptimizeRx

In related news, CEO William J. Febbo purchased 20,000 shares of OptimizeRx stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average price of $5.01 per share, for a total transaction of $100,200.00. Following the transaction, the chief executive officer now directly owns 601,253 shares in the company, valued at approximately $3,012,277.53. This represents a 3.44 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Company insiders own 6.10% of the company’s stock.

Institutional Investors Weigh In On OptimizeRx

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp grew its stake in shares of OptimizeRx by 9.9% during the second quarter. Bank of New York Mellon Corp now owns 111,719 shares of the company’s stock valued at $1,117,000 after purchasing an additional 10,041 shares during the last quarter. Summit Securities Group LLC bought a new position in OptimizeRx in the 2nd quarter worth approximately $25,000. Legato Capital Management LLC lifted its holdings in OptimizeRx by 74.0% during the 2nd quarter. Legato Capital Management LLC now owns 59,693 shares of the company’s stock worth $597,000 after buying an additional 25,377 shares in the last quarter. Rhumbline Advisers boosted its position in OptimizeRx by 9.2% in the 2nd quarter. Rhumbline Advisers now owns 31,462 shares of the company’s stock valued at $315,000 after buying an additional 2,658 shares during the last quarter. Finally, Rice Hall James & Associates LLC increased its stake in shares of OptimizeRx by 23.5% in the 2nd quarter. Rice Hall James & Associates LLC now owns 496,135 shares of the company’s stock valued at $4,961,000 after buying an additional 94,253 shares during the period. Institutional investors and hedge funds own 76.47% of the company’s stock.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.